Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):675–682. doi: 10.1054/bjoc.1999.0980

The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma

H Tsuda 1, K Yamamoto 1, T Inoue 2, I Uchiyama 2, N Umesaki 3
PMCID: PMC2363310  PMID: 10682682

Abstract

We analysed p16 gene alteration and p16, cyclin-dependent kinase 4 (CDK4), CDK6, cyclin D1, cyclin D2, cyclin D3 and retinoblastoma protein (pRb) expression in ten normal endometriums (PE), 18 endometrial hyperplasias (EH) and 35 endometrial cancers (EC). Two of ten PE (20%), nine of 18 EH (50.0%) and 29 of 35 EC (82.9%) exhibited p16 nuclear staining. p16 expression was significantly higher in EC than EH (P = 0.0119). In the six p16 (–) EC, one was considered to have reduced gene dosage consistent with possible homozygous deletion of the CDKN2 gene and three had methylation in 5′CpG island in the promoter region of the p16 gene, whereas none showed such reduced gene dosage and four had methylation in the nine p16 (–) EH. Strong CDK4 staining was observed in 12 of 35 EC (34.3%) and one of 18 EH (5.6%). The strong expression of CDK4 was higher in EC than in EH (P = 0.0399). The expression of CDK4 was higher in EH than PE (P = 0.0054). The abnormalities of p16-cyclin D/CDK-pRb pathway were detected in 18 of 35 EC (51.4%). In conclusion, the expression of p16 and CDK4 may be an early event in the neoplastic transformation of endometrial cancer. © 2000 Cancer Research Campaign

Keywords: p16INK4, cyclin D, CDK, pRb, endometrial cancer

Full Text

The Full Text of this article is available as a PDF (352.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbieri F., Cagnoli M., Ragni N., Pedullà F., Foglia G., Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer. 1997;75(9):1263–1268. doi: 10.1038/bjc.1997.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A. F., Zeuthen J., Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996 Dec 1;56(23):5475–5483. [PubMed] [Google Scholar]
  3. Buckley M. F., Sweeney K. J., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., deFazio A., Watts C. K., Musgrove E. A., Sutherland R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993 Aug;8(8):2127–2133. [PubMed] [Google Scholar]
  4. Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210–212. doi: 10.1038/ng1095-210. [DOI] [PubMed] [Google Scholar]
  5. Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210–212. doi: 10.1038/ng1095-210. [DOI] [PubMed] [Google Scholar]
  6. Campbell I. G., Foulkes W. D., Beynon G., Davis M., Englefield P. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995 Oct 9;63(2):222–225. doi: 10.1002/ijc.2910630213. [DOI] [PubMed] [Google Scholar]
  7. Dutta A., Chandra R., Leiter L. M., Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5386–5390. doi: 10.1073/pnas.92.12.5386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Geradts J., Kratzke R. A., Crush-Stanton S., Wen S. F., Lincoln C. E. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol. 1996 Mar;9(3):339–347. [PubMed] [Google Scholar]
  9. Gillett C., Smith P., Gregory W., Richards M., Millis R., Peters G., Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996 Apr 22;69(2):92–99. doi: 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  10. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  11. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. doi: 10.1016/s0065-230x(08)60352-8. [DOI] [PubMed] [Google Scholar]
  12. He J., Allen J. R., Collins V. P., Allalunis-Turner M. J., Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804–5807. [PubMed] [Google Scholar]
  13. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 Oct 15;55(20):4525–4530. [PubMed] [Google Scholar]
  14. Hui R., Cornish A. L., McClelland R. A., Robertson J. F., Blamey R. W., Musgrove E. A., Nicholson R. I., Sutherland R. L. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996 Jun;2(6):923–928. [PubMed] [Google Scholar]
  15. Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A., Ally D. S., Sheahan M. D., Clark W. H., Jr, Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15–21. doi: 10.1038/ng0994-15. [DOI] [PubMed] [Google Scholar]
  16. Jiang W., Zhang Y. J., Kahn S. M., Hollstein M. C., Santella R. M., Lu S. H., Harris C. C., Montesano R., Weinstein I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9026–9030. doi: 10.1073/pnas.90.19.9026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kamb A. Cell-cycle regulators and cancer. Trends Genet. 1995 Apr;11(4):136–140. doi: 10.1016/s0168-9525(00)89027-7. [DOI] [PubMed] [Google Scholar]
  18. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  19. Kinoshita I., Dosaka-Akita H., Mishina T., Akie K., Nishi M., Hiroumi H., Hommura F., Kawakami Y. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 1996 Dec 15;56(24):5557–5562. [PubMed] [Google Scholar]
  20. Kratzke R. A., Greatens T. M., Rubins J. B., Maddaus M. A., Niewoehner D. E., Niehans G. A., Geradts J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996 Aug 1;56(15):3415–3420. [PubMed] [Google Scholar]
  21. Li Y., Nichols M. A., Shay J. W., Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994 Dec 1;54(23):6078–6082. [PubMed] [Google Scholar]
  22. Maestro R., Boiocchi M. Sunlight and melanoma: an answer from MTS1 (p16) Science. 1995 Jan 6;267(5194):15–16. doi: 10.1126/science.7809600. [DOI] [PubMed] [Google Scholar]
  23. Marchini S., Codegoni A. M., Bonazzi C., Chiari S., Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer. 1997;76(2):146–149. doi: 10.1038/bjc.1997.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry J. A., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed] [Google Scholar]
  25. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  26. Milde-Langosch K., Riethdorf L., Bamberger A. M., Löning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch. 1999 Jan;434(1):23–28. doi: 10.1007/s004280050300. [DOI] [PubMed] [Google Scholar]
  27. Müller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2945–2949. doi: 10.1073/pnas.91.8.2945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nakagawa K., Conrad N. K., Williams J. P., Johnson B. E., Kelley M. J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 1995 Nov 2;11(9):1843–1851. [PubMed] [Google Scholar]
  29. Niemann T. H., Yilmaz A. G., McGaughy V. R., Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol. 1997 May;65(2):232–236. doi: 10.1006/gyno.1997.4664. [DOI] [PubMed] [Google Scholar]
  30. Peiffer S. L., Bartsch D., Whelan A. J., Mutch D. G., Herzog T. J., Goodfellow P. J. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog. 1995 Aug;13(4):210–212. doi: 10.1002/mc.2940130403. [DOI] [PubMed] [Google Scholar]
  31. Pietiläinen T., Lipponen P., Aaltomaa S., Eskelinen M., Kosma V. M., Syrjänen K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur J Cancer. 1995;31A(3):329–333. doi: 10.1016/0959-8049(94)00463-f. [DOI] [PubMed] [Google Scholar]
  32. Prall O. W., Sarcevic B., Musgrove E. A., Watts C. K., Sutherland R. L. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem. 1997 Apr 18;272(16):10882–10894. doi: 10.1074/jbc.272.16.10882. [DOI] [PubMed] [Google Scholar]
  33. Schauer I. E., Siriwardana S., Langan T. A., Sclafani R. A. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7827–7831. doi: 10.1073/pnas.91.16.7827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  35. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  36. Shigemasa K., Hu C., West C. M., Clarke J., Parham G. P., Parmley T. H., Korourian S., Baker V. V., O'Brien T. J. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig. 1997 Mar-Apr;4(2):95–102. [PubMed] [Google Scholar]
  37. Shiozawa T., Nikaido T., Shimizu M., Zhai Y., Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer. 1997 Dec 15;80(12):2250–2256. doi: 10.1002/(sici)1097-0142(19971215)80:12<2250::aid-cncr5>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  38. Sicinski P., Donaher J. L., Parker S. B., Li T., Fazeli A., Gardner H., Haslam S. Z., Bronson R. T., Elledge S. J., Weinberg R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995 Aug 25;82(4):621–630. doi: 10.1016/0092-8674(95)90034-9. [DOI] [PubMed] [Google Scholar]
  39. Strauss M., Lukas J., Bartek J. Unrestricted cell cycling and cancer. Nat Med. 1995 Dec;1(12):1245–1246. doi: 10.1038/nm1295-1245. [DOI] [PubMed] [Google Scholar]
  40. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671. doi: 10.1038/369669a0. [DOI] [PubMed] [Google Scholar]
  41. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995 May 5;81(3):323–330. doi: 10.1016/0092-8674(95)90385-2. [DOI] [PubMed] [Google Scholar]
  42. Yaginuma Y., Katayama H., Kawai K., Duenas J. C., Ishikawa M. Analysis of the retinoblastoma gene in human endometrial carcinoma. Obstet Gynecol. 1996 May;87(5 Pt 1):755–759. doi: 10.1016/0029-7844(96)00010-5. [DOI] [PubMed] [Google Scholar]
  43. Yao J., Pollock R. E., Lang A., Tan M., Pisters P. W., Goodrich D., El-Naggar A., Yu D. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 1998 Apr;4(4):1065–1070. [PubMed] [Google Scholar]
  44. Zhang T., Nanney L. B., Luongo C., Lamps L., Heppner K. J., DuBois R. N., Beauchamp R. D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997 Jan 1;57(1):169–175. [PubMed] [Google Scholar]
  45. Zukerberg L. R., Yang W. I., Gadd M., Thor A. D., Koerner F. C., Schmidt E. V., Arnold A. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol. 1995 Jun;8(5):560–567. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES